Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.86 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.86 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.86 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.86 |
| ▸ | TTR | P02766 | 3/20 | 0.86 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.85 |
| ▸ | NQO2 | P16083 | 4/20 | 0.78 |
| ▸ | ABL1 | P00519 | 3/20 | 0.78 |
| ▸ | BCR | P11274 | 3/20 | 0.78 |
| ▸ | ESR1 | P03372 | 2/20 | 0.78 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | AHR | P35869 | 2/20 | 0.78 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.78 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.78 |
| ▸ | TUBB | P07437 | 1/20 | 0.78 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29652111 | 1.00 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL2516446 | 1.00 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL2516449 | 1.00 | PTGS2 (0.86) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL562335 | 0.92 | CYP1A1 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL30475363 | 0.92 | CYP1A1 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL562336 | 0.92 | CYP1A1 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| Resveratrol 4'-Methyl Ether SCHEMBL4732963 | 0.92 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| Resveratrol 4'-Methyl Ether SCHEMBL563262 | 0.92 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| Resveratrol 4'-Methyl Ether SCHEMBL563261 | 0.92 | PTGS2 (1.00) | PTGS2CYP1A1CYP1B1ALOX5TTR | |
| SCHEMBL28899386 | 0.92 | PTGS2 (0.73) | PTGS2CYP1A1CYP1B1ALOX5TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | claimed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | claimed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | claimed |
| EP-4687856-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS Therapeutics, LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240366525-A1 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| WO-2024229159-A2 | GLP-1R AGONIST AND DPP-4 INHIBITOR COMPOSITIONS AND METHODS OF USING | JDS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-111728962-B | Resveratrol derivative and medical application thereof in resisting fibrosis | 绍兴君科臻元医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20220185764-A1 | Resveratrol derivative and anti-fibrotic method using the same | TAIZHOU HUAYUAN MEDICINAL TECH CO. LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185764-A1 | Resveratrol derivative and anti-fibrotic method using the same | REN, RXFP1, RXFP3 | PTGS2 2867/4885CYP1A1 724/4885CYP1B1 1367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.